Premium
[P4–472]: WHAT IS DEMENTIA FRIENDLY? DEVELOPMENT AND VALIDATION OF A NOVEL TOOL TO MEASURE STIGMA ASSOCIATED WITH DEMENTIA
Author(s) -
Hayward Dominique,
Howell J.Christina,
Hu William T.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.633
Subject(s) - dementia , inclusion (mineral) , stigma (botany) , focus group , psychology , psychiatry , medicine , gerontology , social psychology , business , disease , pathology , marketing
CSF NANT biomarkers associated with AD. Using CSF collected from subjects with normal cognition (NC), very mild dementia/ CDR0.5/mild cognitive impairment (MCI), AD dementia, and other non-AD dementia (OD) recruited from three Alzheimer’s Disease Centers, we qualified nine immunoassays to identify stage-dependent biomarkers of AD. Results:Each of the 125 subjects was examined according to clinical diagnosis and CSF AD biomarker profiles. Symptomatic subjects with AD had greater CSF levels of fatty acid binding protein 3, neurofilament light chain (NfL), and interleukin 7 than asymptomatic subjects with AD. Regardless of CSFAD biomarker profiles, NfL levels were highest in dementia and lowest in NC. Conclusions:When combined with amyloid and tau levels, CSF NANT biomarkers can distinguish between pre-symptomatic, MCI, and dementia stages of AD and nonAD disorders.